Norvēģija - norvēģu - Statens legemiddelverk

ferring legemidler as - menotropin, humant - pulver og væske til injeksjonsvæske, oppløsning - 150 iu

Norvēģija - norvēģu - Statens legemiddelverk

sandoz - københavn - valsartan / hydroklortiazid - tablett, filmdrasjert - 80 mg / 12.5 mg

Norvēģija - norvēģu - Statens legemiddelverk

sandoz - københavn - valsartan / hydroklortiazid - tablett, filmdrasjert - 160 mg / 12.5 mg

Norvēģija - norvēģu - Statens legemiddelverk

sandoz - københavn - valsartan / hydroklortiazid - tablett, filmdrasjert - 160 mg / 25 mg

Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

amarin pharmaceuticals ireland limited - icosapent ethyl - dyslipidemiene - lipid modifiserende midler - indicated to reduce cardiovascular risk as an adjunct to statin therapy.

Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

zoetis belgium sa - selamectin, sarolaner - antiparasitic products, insektmidler og repellents, macrocyclic lactones, , kombinasjoner - katter - for katter med eller i fare av blandede parasittiske infestasjoner ved flått og lopper, luer, kvaler, gastrointestinale nematoder eller hjerteorm. veterinærpreparatet er utelukkende indikert når bruk mot flått og en eller flere av de andre målparasittene er indikert samtidig.

Norvēģija - norvēģu - Statens legemiddelverk

karo pharma as - paracetamol - tablett, filmdrasjert - 500 mg

Norvēģija - norvēģu - Statens legemiddelverk

intervet international b.v. - altrenogest - mikstur, oppløsning - 2.2 mg/ ml

Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

zoetis belgium sa - selamectin, sarolaner - antiparasittiske produkter, insektmidler og repellenter - katter - for katter med eller i fare av blandede parasittiske infestasjoner ved flått og lopper, luer, kvaler, gastrointestinale nematoder eller hjerteorm. veterinærpreparatet er utelukkende indikert når bruk mot flått og en eller flere av de andre målparasittene er indikert samtidig.

Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - graft-avvisning - immunsuppressive - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.